JUL 29, 2020 10:30 AM PDT

Will We Have a COVID-19 Vaccine by Year-End?

WRITTEN BY: Annie Lennon

This week, pharmaceutical companies Moderna and Pfizer launched giant Phase III 30,000-subject trials for their COVID-19 vaccines. Both say that their vaccines may be available for general use by the end of the year. 

The vaccines are based upon a relatively new practice in which synthetic molecules that mimic the coronavirus are injected into patients instead of the virus itself. In doing so, they teach the immune system to fend off the real thing, while being safe from potential side effects of having it introduced to the body. 

Although faster than traditional production methods and thus easily scalable, as the practice is relatively new, it does not have an extensive track record for efficacy. 

Nevertheless, announcements for the trials come as a part of the US government-funded COVID-19 Prevention Network that plans to roll out studies of leading vaccine candidates every month- each with 30,000 newly recruited volunteers. Aside from seeing if the vaccines work, researchers hope to verify each vaccine's safety profile and then compare results. 

All of this means that large numbers of people will be required to partake in trials, which can often be problematic. Dr. Larry Corey, a virologist who helps oversee the study sites, has said, however, that over 150,000 Americans have already signaled interest in the treatment in online registries. 

While Moderna has received almost $1 billion from the US government to help roll out its vaccine, Pfizer has agreed to sell enough vaccines for 50 million people in the US for around $2 billion should their vaccine work. 

Pfizer has also said that it aims to have around 1.3 billion doses available by the end of 2021- enough to treat 650 million people at two doses each. Meanwhile, Moderna aims to manufacture between 500 million and 1 billion doses per year.

 

Sources: CNBCWashington PostReuters

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 22, 2022
Coronavirus
Researchers Say Nasal Boosters Will be Important to Stopping COVID
JUL 22, 2022
Researchers Say Nasal Boosters Will be Important to Stopping COVID
The SARS-CoV-2 virus has continued to evolve since the start of the pandemic, and we've moved down the list of variants ...
JUL 23, 2022
Drug Discovery & Development
Antibiotics Affect Gut Microbiome of Male and Female Rats Differently
JUL 23, 2022
Antibiotics Affect Gut Microbiome of Male and Female Rats Differently
Antibiotics induce sex-specific effects on the gut microbiome of male and female rats. The corresponding study was publi ...
JUL 24, 2022
Microbiology
Host Cell Proteins That Aid Lassa Virus & A Way to Stop One of Them
JUL 24, 2022
Host Cell Proteins That Aid Lassa Virus & A Way to Stop One of Them
Lassa virus infections are asymptomatic in about 80 percent of people. But the virus also causes Lassa fever (LF), which ...
SEP 21, 2022
Cancer
Technology for Monitoring Tumors in Pre-Clinical Studies
SEP 21, 2022
Technology for Monitoring Tumors in Pre-Clinical Studies
Pre-clinical modeling, often using laboratory mice, is essential in developing life-saving therapies to treat cancer and ...
OCT 04, 2022
Clinical & Molecular DX
Alcohol Use Disorder Could Be Treated with Heart Medication
OCT 04, 2022
Alcohol Use Disorder Could Be Treated with Heart Medication
In a recent study published in Molecular Psychiatry, an international team of researchers led by Johns Hopkins Universit ...
OCT 04, 2022
Cancer
The NCI Welcomes First Woman Director: Monica M. Bertagnolli, MD
OCT 04, 2022
The NCI Welcomes First Woman Director: Monica M. Bertagnolli, MD
In August, President Biden announced his intention to appoint Dr. Monica M. Bertagnolli as the newest director of the Na ...
Loading Comments...